Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study.

Autor: Palmer ME; Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA., Gile JJ; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA., Storandt MH; Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA., Jin Z; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA., Zemla TJ; Department of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA., Tran NH; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA., Mahipal A; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.; Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Oct 06; Vol. 15 (19). Date of Electronic Publication: 2023 Oct 06.
DOI: 10.3390/cancers15194867
Abstrakt: Background: Lenvatinib, a multikinase inhibitor, is an FDA-approved treatment for advanced hepatocellular carcinoma (HCC) in the first-line setting. Recent trial data have established atezolizumab plus bevacizumab as well as tremelimumab plus durvalumab as preferred first-line treatment options for advanced HCC. The role of lenvatinib following progression on immunotherapy in patients with advanced HCC remains unclear.
Methods: We conducted a multicentric, retrospective analysis of patients with advanced HCC diagnosed between 2010 and 2021 at the Mayo Clinic in Minnesota, Arizona, and Florida who received immunotherapy followed by lenvatinib. Median overall survival and progression-free survival analyses were performed using the Kaplan-Meier method, and responses were determined using RECIST 1.1. Adverse events were determined using CTCAE v 4.0.
Results: We identified 53 patients with advanced HCC who received lenvatinib following progression on immunotherapy. Forty five (85%) patients had a Child Pugh class A at diagnosis, while 30 (58%) patients were still Child Pugh A at time of lenvatinib initiation. Lenvatinib was administered as a second-line treatment in 85% of the patients. The median PFS was 3.7 months (95% CI: 3.2-6.6), and the median OS from the time of lenvatinib initiation was 12.8 months (95% CI: 6.7-19.5). In patients with Child Pugh class A, the median OS and PFS was 14 and 5.2 months, respectively. Race, gender, and Child Pugh class was associated with OS on multivariate analysis.
Discussion: Our study, using real-world data, suggests that patients benefit from treatment with lenvatinib following progression on immunotherapy in advanced HCC. The optimal sequencing of therapy for patients with advanced HCC following progression on immunotherapy remains unknown, and these results need to be validated in a clinical trial.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje